"Generex continues to make progress toward the planned spin-out of NuGenerex Immuno-Oncology (NGIO) and is in discussions with two potential partners with novel, exciting immuno-oncology platforms and clinical stage product development programs. Mr. Moscato will provide details outlining the company’s strategic plan and timing for the NGIO spin-out."

Sounds exciting.